Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study
Scandinavian Journal of Surgery · 2024-06 · 113 (2) · 140-149
DOI: 10.1177/14574969231200653 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Scandinavian Journal of Surgery, online erschienen am 12.10.2023. Verfasst von Antti Yrjönen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Jorvi Hospital, Ambulatory Surgery Unit, Karvasmäentie 8, Espoo 02740 Finland. Hauptthemen laut MEDLINE: Pseudomyxoma Peritonei, Cytoreduction Surgical Procedures, Peritoneal Neoplasms, Hyperthermic Intraperitoneal Chemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims: Pseudomyxoma peritonei (PMP) is a rare disease characterized by progressive build-up of mucinous deposits inside the abdominal cavity. The aim of this study was to investigate the effect of disease recurrence on overall survival in patients with PMP after cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
Methods
One-hundred thirty-two consecutive PMP patients treated with CRS + HIPEC at Helsinki University Hospital between 2008 and 2017 were included. The impact of clinicopathological and treatment-related characteristics on recurrence and overall survival was evaluated.
Results
The median follow-up time in the study was 5.04 (range = 0.05–11.60) years. In 121 (91.7%) patients, the disease was classified as low grade and 11 (8.3%) had high-grade disease. In the low-grade group, 26 (21.5%) patients developed a recurrence during follow-up compared to 6 (54.5%) patients in the high-grade group. In the low-grade group, cumulative survival was 98.2%, 91.4%, and 91.4% at 3, 6, and 8 years, respectively. In the high-grade group, cumulative survival was 90.0% and 78.8% at 3 and 6 years, respectively. In patients with recurrent disease, the cumulative survival was 100%, 84.6%, and 84.6% at 3, 6, and 8 years in the low-grade category and 80.0% and 60.0% at 3 and 6 years in the high-grade category, respectively. In the low-grade group, a statistically significant correlation with recurrence but not with overall survival was identified with peritoneal cancer index (PCI), carcinoembryonic antigen (CEA), and the number of affected regions.
Conclusion
The recurrence of low-grade PMP does not significantly affect overall survival of patients. Disease extent may not be a prognostic indicator after curative CRS and HIPEC in low-grade PMP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jorvi Hospital, Ambulatory Surgery Unit, Karvasmäentie 8, Espoo 02740 Finland.
- Abdominal Center, Department of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
ORCID-Profile: Antti Yrjönen, Carola Haapamäki
Zitieren
APA
Yrjönen, A., Koskenvuo, L., Haapamäki, C., & Lepistö, A. (2024). Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study. Scandinavian Journal of Surgery, 113(2), 140-149. https://doi.org/10.1177/14574969231200653
Vancouver
Yrjönen A, Koskenvuo L, Haapamäki C, Lepistö A. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study. Scandinavian Journal of Surgery. 2024;113(2):140-149. doi:10.1177/14574969231200653
BibTeX
@article{Yrjnen2024,
author = {Yrjönen, Antti and Koskenvuo, Laura and Haapamäki, Carola and Lepistö, Anna},
title = {Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study},
journal = {Scandinavian Journal of Surgery},
year = {2024},
volume = {113},
number = {2},
pages = {140--149},
doi = {10.1177/14574969231200653}
}
EUVIMED